Institution
Wayne State University
Education•Detroit, Michigan, United States•
About: Wayne State University is a education organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 42801 authors who have published 82738 publications receiving 3083713 citations. The organization is also known as: WSU & Wayne University.
Topics: Population, Cancer, Poison control, Pregnancy, Medicine
Papers published on a yearly basis
Papers
More filters
Cornell University1, Memorial Sloan Kettering Cancer Center2, University of Chicago3, New York University4, Harvard University5, Wayne State University6, University of Washington7, Fred Hutchinson Cancer Research Center8, Icahn School of Medicine at Mount Sinai9, Johns Hopkins University School of Medicine10, Seattle Genetics11, Astellas Pharma12, Yale Cancer Center13
TL;DR: Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti–PD-1/L1 therapy.
Abstract: PURPOSELocally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–program...
360 citations
TL;DR: It is shown that even though all the dendrimers are taken up by fluid-phase endocytosis, significant differences in uptake mechanisms exist, which open up new possibilities of targeting therapeutic agents to specific cell organelles based on surface charge.
360 citations
Wayne State University1, Stony Brook University2, University of Connecticut3, Harvard University4, Max Planck Society5, University of Kiel6, University College Cork7, Swarthmore College8, University of Vermont9, Indiana University10, York University11, University of Rennes12, Tel Aviv University13, Vanderbilt University14
TL;DR: Holobionts and hologenomes are incontrovertible, multipartite entities that result from ecological, evolutionary, and genetic processes at various levels that constitute a wider vocabulary and framework for host biology in light of the microbiome.
Abstract: Given the complexity of host-microbiota symbioses, scientists and phi- losophers are asking questions at new biological levels of hierarchical organization— what is a holobiont and hologenome? When should this vocabulary be applied? Are these concepts a null hypothesis for host-microbe systems or limited to a certain spectrum of symbiotic interactions such as host-microbial coevolution? Critical dis- course is necessary in this nascent area, but productive discourse requires that skep- tics and proponents use the same lexicon. For instance, critiquing the hologenome concept is not synonymous with critiquing coevolution, and arguing that an entity is not a primary unit of selection dismisses the fact that the hologenome concept has always embraced multilevel selection. Holobionts and hologenomes are incontro- vertible, multipartite entities that result from ecological, evolutionary, and genetic processes at various levels. They are not restricted to one special process but consti- tute a wider vocabulary and framework for host biology in light of the microbiome.
360 citations
Roswell Park Cancer Institute1, Stanford University2, Santa Clara Valley Medical Center3, University of Texas Health Science Center at Houston4, Wayne State University5, University of Genoa6, National Institutes of Health7, Katholieke Universiteit Leuven8, University of Texas Health Science Center at San Antonio9, Duke University10, University of Paris11, University of Florida12, University of Lausanne13, University of Michigan14, Harvard University15, University of Alabama16, University of Texas MD Anderson Cancer Center17, University of Milan18, Medical University of Vienna19, University of Manitoba20, Radboud University Nijmegen21
TL;DR: An expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes.
Abstract: Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.
360 citations
360 citations
Authors
Showing all 43073 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Robert Langer | 281 | 2324 | 326306 |
| Eugene Braunwald | 230 | 1711 | 264576 |
| Rakesh K. Jain | 200 | 1467 | 177727 |
| Anil K. Jain | 183 | 1016 | 192151 |
| Richard A. Gibbs | 172 | 889 | 249708 |
| Bradley Cox | 169 | 2150 | 156200 |
| Jun Wang | 166 | 1093 | 141621 |
| David Altshuler | 162 | 345 | 201782 |
| Elliott M. Antman | 161 | 716 | 179462 |
| Jovan Milosevic | 152 | 1433 | 106802 |
| Roberto Romero | 151 | 1516 | 108321 |
| Kypros H. Nicolaides | 147 | 1302 | 87091 |
| John F. Hartwig | 145 | 714 | 66472 |
| Charles Maguire | 142 | 1197 | 95026 |
| Mingshui Chen | 141 | 1543 | 125369 |